What are the absolute and relative contraindications of escitalopram (Lexapro)?

Absolute and Relative Contraindications of Escitalopram

Escitalopram is absolutely contraindicated with concurrent MAOI use (including linezolid and IV methylene blue), with pimozide, and in patients with known hypersensitivity to escitalopram or citalopram. 1

Absolute Contraindications

The FDA label clearly defines the following as absolute contraindications 1:

• Concurrent use with MAOIs or within 14 days of discontinuing either escitalopram or an MAOI intended to treat psychiatric disorders (due to fatal serotonin syndrome risk)
• Linezolid or intravenous methylene blue (both have MAOI properties)
• Pimozide (due to QT prolongation risk)
• Known hypersensitivity to escitalopram, citalopram, or any inactive ingredients

The 14-day washout period is critical—at least 14 days must elapse between stopping an MAOI and starting escitalopram, and vice versa 1.

Relative Contraindications and High-Risk Situations

Based on guideline evidence, exercise extreme caution or avoid escitalopram in 2:

Psychiatric Conditions

• Prior serotonin syndrome or neuroleptic malignant syndrome - these patients have demonstrated vulnerability to serotonergic toxicity
• Bipolar disorder (undiagnosed or inadequately treated) - screen all patients for personal/family history of bipolar disorder, mania, or hypomania before initiating treatment 1, as antidepressants can precipitate manic episodes 3
• Active psychotic disorder - SSRIs should not be administered 4

Cardiac Conditions

• Long QT syndrome - escitalopram and citalopram can prolong QT interval and should be avoided in patients with congenital or acquired long QT syndrome 3
• Concurrent use with other QT-prolonging drugs - SSRIs (especially citalopram/escitalopram) may interact with drugs that prolong QT interval 3
• Uncontrolled cardiac arrhythmias - given the QT prolongation risk 5

Neurological Conditions

• Uncontrolled seizure disorder - SSRIs should be used cautiously in patients with seizure history; initiate only after seizures are controlled with anticonvulsants 3

Medical Comorbidities

• Severe hepatic impairment - maximum dose should be limited to 10 mg daily 1
• Severe renal impairment (creatinine clearance <20 mL/min) - recommended dosage has not been determined 1
• Uncontrolled hyponatremia - SSRIs can worsen this condition 2

Bleeding Risk

• Concurrent use with aspirin, NSAIDs, or anticoagulants - SSRIs increase bleeding risk, including rare events like ecchymosis, epistaxis, petechiae, and hemorrhage 3

Critical Drug-Drug Interactions Requiring Avoidance

Beyond MAOIs, avoid or use extreme caution when combining escitalopram with 3:

Other serotonergic agents (risk of serotonin syndrome):

• Other SSRIs, SNRIs, or tricyclic antidepressants
• Opioids: tramadol, meperidine, methadone, fentanyl
• Triptans (migraine medications)
• Stimulants (amphetamines, possibly methylphenidate)
• Dextromethorphan, chlorpheniramine
• St. John's Wort, L-tryptophan
• Buspirone, lithium
• Illicit drugs: MDMA (ecstasy), methamphetamine, cocaine, LSD

Important clinical pearl: When combining two non-MAOI serotonergic drugs is unavoidable, start the second agent at a low dose, increase slowly, and monitor intensively for serotonin syndrome symptoms in the first 24-48 hours after any dosage change 3.

Special Populations Requiring Dose Adjustment

• Elderly patients: Maximum recommended dose is 10 mg daily 5, 1
• Hepatic impairment: Maximum dose 10 mg daily 1
• Adolescents and young adults (<25 years): Increased risk of suicidal thoughts and behaviors—requires close monitoring, especially in first few months 1

Common Pitfalls to Avoid

1. Failing to screen for bipolar disorder before initiating treatment—this can precipitate dangerous manic episodes 1
2. Abrupt discontinuation—always taper gradually to avoid discontinuation syndrome (though escitalopram has lower risk than paroxetine) 3
3. Overlooking the 14-day MAOI washout period—this is an absolute requirement, not a suggestion 1
4. Ignoring QT prolongation risk in elderly patients or those on multiple medications 5

Note: While escitalopram has the least effect on CYP450 isoenzymes compared to other SSRIs and thus lower propensity for drug interactions 3, the serotonin syndrome risk with MAOIs and other serotonergic agents remains absolute and potentially fatal.